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Sir
MMC, a product of Streptomyces caespitosus, is known to be one
of the most active agents for various neoplasms and has been
widely used throughout the world for over 40 years (Wakaki et al,
1958; Hortobagyi, 1985). Recently, however, we have noticed an
unexpected increase in MMC’s toxicity. Although the reasons for
this are under investigation, we feel it necessary to draw this
matter to the attention of clinicians who prescribe the drug. 
From 1990 to 1996, we performed a prospective randomized
clinical trial comparing the effects of CMF versus MMC plus
CMF (MCMF) in the treatment of node-positive, premenopausal
breast cancer patients (age ≤ 50) in an adjuvant setting after
obtained informed consent. In the MCMF group, the dose and
time schedule of MMC was 14 mg/m2 on day 1 immediately after
surgery, and 8 mg/m2 on day 2, and 6 cycles of CMF
chemotherapy were started after recovery from the toxicity of
MMC, usually after one month. Total enrolled number of patients
was 283. The main toxic effect of MMC monotherapy was bone
marrow suppression, but patients were well tolerated during the
course of the trial. After a median follow-up of 5.7 years, a statis-
tically significant advantage of MMC plus CMF over CMF alone
in relapse-free survival was observed (P = 0.0058), but not in
overall survival (the 36th ASCO #364). After the end of the trial,
we adopted a MCMF regimen as a standard therapy for patients in
the same condition in view of the favorable results obtained.
However, this time we noticed a gradual, and unexpected but
significant increase of MMC related bone marrow toxicity from
about 1995 or 1996 (Figure 1). 
As the change in toxicity was unequivocal, we tried to clarify its
causes. In a survey of possible dependent factors, no apparent
differences were revealed regarding the distribution of patient age,
disease stage, actually administered dose, or time schedule of
administration between patients who participated in the trial and
recent non-trial patients, or between patients who developed grade
III/IV toxicity and those who did not. Following this, another two
possible causes were explored. First, we tested the consistency of
the quality of MMC itself against various lots of products physic-
ally and chemically using spectrography (HPLC), chromato-
graphy, net weight deviation, and bioassay of MMC’s power
against bacteria, but we found no differences. The company
(Kyowa Hakko Kogyo Co) carried out an in vivo animal toxicity
test using BALB/C mice, but the results showed no differences in
the bone marrow toxicity between product lots produced in 1994,
1997 and 1998. Secondly, since drugs other than cytostatics used
concomitantly during the course of MMC treatment might affect
its toxicity, these 82 drugs were surveyed. Several drugs including
antiserotonin agents and an anesthetic were frequently used in the
grade III/IV toxicity group, but no clear conclusions could be
obtained yet. An in vivo animal toxicity test of MMC together
with these potential drugs is now being carried out. 
In conclusion, MMC should be used with caution whatever the
reason for its increase in toxicity. 
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Figure 1 Trends of the mean nadir levels of white blood cells and platelet
counts each year following MMC treatment. A significant decrease of the
mean nadir levels of white blood cell counts is seen in 1997–1998 and in
platelets counts in 1995–1998 compared to those of 1990–1991, respectively
(*: P < 0.01, **: P < 0.0001). Grade III/IV bone marrow toxicity was seen in
6% (8/135) of patients during the course of 1990–1996, whereas it was seen
in 35% (15/43) during 1997–1998 (P < 0.0001). Patients who had previously
been administered anti-cancer drugs and who had had diseases that might
affect bone marrow function are excluded from the data